# EDGAR Filing Document

**Accession Number:** 0001889791
**File Stem:** 0001493152-25-021494
**Filing Date:** 2025-11
**Character Count:** 2810
**Document Hash:** 0d55582d023602bccc7e79c469896cd8
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-25-021494.hdr.sgml**: 20251110

**ACCESSION NUMBER**: 0001493152-25-021494

**CONFORMED SUBMISSION TYPE**: DEL AM

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20251110

**DATE AS OF CHANGE**: 20251110

**EFFECTIVENESS DATE**: 20251110

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** INNOCAN PHARMA Corp
- **CENTRAL INDEX KEY:** 0001889791
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** Z4
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** DEL AM
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-288899
- **FILM NUMBER:** 251466007

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 1015, 926 - 5 AVENUE SW
- **CITY:** CALGARY
- **PROVINCE COUNTRY:** Z4
- **ZIP:** T2P 0N7
- **BUSINESS PHONE:** 403-777-1519

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 1015, 926 - 5 AVENUE SW
- **CITY:** CALGARY
- **PROVINCE COUNTRY:** Z4
- **ZIP:** T2P 0N7

Innocan Pharma Corporation

1015, 926 – 5 Avenue SW

Calgary, Alberta T2P 0N7, Canada

November 10, 2025

*<u>Via EDGAR</u>*

Securities and Exchange Commission

Division of Corporate Finance

100 F Street, NE

Washington, D.C. 20549

RE: Innocan Pharma Corporation (CIK 0001889791) <br> <u>Registration Statement No. 333-288899 on Form F-1 (the "Registration Statement")</u>

Ladies and Gentlemen:

Reference is made to the Registration Statement on Form F-1 (Amendment No. 4) (File No. 333-288899) filed by Innocan Pharma Corporation on October 22, 2025 (the "Registration Statement").

Pursuant to Rule 473(c) of the Securities Act of 1933 (the "Act"), the following delaying amendment, prescribed by Rule 473(a) of the Act, is hereby incorporated into the facing page of the Registration Statement:

"**The registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until the Registration Statement shall become effective on such date as the Commission, acting pursuant to said Section 8(a), may determine."**

Should you have any questions regarding the Registration Statement, please feel free to contact the undersigned at +1 312-364-1633.

Yours sincerely,

---

| | |
|:---|:---|
| Very truly yours, | Very truly yours, |
| INNOCAN PHARMA CORPORATION | INNOCAN PHARMA CORPORATION |
| By: | */s/ Iris Bincovich* |
|  | Iris Bincovich |
|  | Chief Executive Officer |

---

cc: David Huberman (Greenberg Traurig, LLP)